Currently, there are 228.36M common shares owned by the public and among those 227.36M shares have been available to trade.
The company’s stock has a 5-day price change of -1.56% and 88.32% over the past three months. LCTX shares are trading 2.31% year to date (YTD), with the 12-month market performance up to 86.11% higher. It has a 12-month low price of $0.37 and touched a high of $1.15 over the same period. LCTX has an average intraday trading volume of 1.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.94%, 49.77%, and 42.12% respectively.
Institutional ownership of Lineage Cell Therapeutics Inc (AMEX: LCTX) shares accounts for 48.65% of the company’s 228.36M shares outstanding.
It has a market capitalization of $213.56M and a beta (3y monthly) value of 1.61. The earnings-per-share (ttm) stands at -$0.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.94% over the week and 10.70% over the month.
Analysts forecast that Lineage Cell Therapeutics Inc (LCTX) will achieve an EPS of -0.03 for the current quarter, -0.03 for the next quarter and -0.06 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.04 while analysts give the company a high EPS estimate of -0.04. Comparatively, EPS for the current quarter was -0.03 a year ago. Earnings per share for the fiscal year are expected to decrease by -9.73%, and 49.86% over the next financial year. EPS should grow at an annualized rate of 9.01% over the next five years, compared to -2.93% over the past 5-year period.
Looking at the support for the LCTX, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on August 20, 2024, with the firm’s price target at $4. Robert W. Baird coverage for the Lineage Cell Therapeutics Inc (LCTX) stock in a research note released on November 02, 2022 offered a Outperform rating with a price target of $5. B. Riley Securities was of a view on June 14, 2022 that the stock is Buy, while Noble Capital Markets gave the stock Outperform rating on August 19, 2021, issuing a price target of $8. Cantor Fitzgerald on their part issued Overweight rating on March 31, 2021.
